|
|
|
 |
| |
Resources/ Links |
|
 |
 |
This section contains a host of resources that may be useful for you, your practice, and your patients. Click on the links below to find information relevant to your needs. |
|
 |
|
 |
|
Resources for you, where you can access the following information:
Acromegaly
Gastro-entero-pancreatic neuroendocrine (GEP NE) tumours
- Clinical slide presentation on gastro-entero-pancreatic neuroendocrine (GEP NE) tumours: Neuroendocrine Gut and Pancreatic Tumours: Tumour Biology, Diagnosis and Treatment
Endocrine and pituitary
- Our Endocrine and Pituitary Newsletter
- Links to professional organizations
|
|
|
|
Resources for your patients, where you can access the following information:
Acromegaly
- Links to general information
- Acromegaly patient education material (PDF) - can be downloaded and printed for your patients
GEP NE Tumours
- Links to general information
- GEP NE patient education material (PDF) - can be downloaded
and printed for your patients
- GEP NE Tumor article in English,
Spanish,
French,
Italian
and German.
A Checklist for Your Patients
Acromegaly |
GEP NE Tumours |
- Somatostatin analogue therapy such as Sandostatin® LAR® works at the site of the tumour to control growth hormone (GH) secretion and cell growth.
- Sandostatin® LAR® treats many of the symptoms of acromegaly, including headache, fatigue, joint pain, and perspiration.
- Many patients treated with Sandostatin® LAR® have improved heart function and exercise capacity and duration.
- Convenient, once-monthly administration with Sandostatin® LAR® may lead to better patient compliance.
- Sandostatin® LAR® has a well-established safety profile backed by a decade of use.
|
- Somatostatin analogue therapy such as Sandostatin® LAR® works at the site of GEP NE tumours to control gastrointestinal hormone secretion and affect tumour growth.
- Sandostatin® LAR® controls symptoms after the first
dose, significantly reducing the frequency of diarrhoea
and flushing.Data on file, Novartis Pharma AG
- Convenient, once-monthly administration with Sandostatin® LAR® may lead to better patient compliance.
- Sandostatin® LAR® has a well-established safety profile backed by a decade of use.
|
|
|
|
|
Glossary of terms pertaining to acromegaly and GEP NE tumours. |
|
|
|
FAQ
Frequently asked questions and answers about the causes, diagnosis and treatment of acromegaly, GEP NE tumours and carcinoid syndrome. |
|
|
|
|
|
|
|
|
|
|
